NTHI: IOVA lifts 2026 guide; NTHI schedules Nov 17 FDA meeting; Summit gets $2B AstraZeneca investment ahead of Nov 14 PDUFA

AI Summary

This note flags three near-term biotech catalysts: Iovance (IOVA) raised 2026 revenue guidance to $410–$420M driven by stronger demand for Amtagvi and Proleukin and an expanding treatment-center network, suggesting commercial-scale execution. NeOnc (NTHI) has an End-of-Phase 1 Type B FDA meeting set for Nov 17 for NEO212 after a Phase 1 recommended Phase 2 dose and positive NEO100 Phase 2a topline signals, while Summit (SMMT) secured a $2B convertible-preferred investment and clinical collaboration with AstraZeneca and faces a Nov 14 PDUFA for ivonescimab plus chemo in EGFR‑mut NSCLC.

Positives

IOVA raised full-year 2026 revenue guidance to $410–$420M, implying ~60% YoY growth and showing commercial demand for Amtagvi/Proleukin
NTHI has a dated Nov 17 End-of-Phase 1 FDA meeting for NEO212 and reported supportive NEO100 Phase 2a topline (6‑month PFS beat vs 20% benchmark)
SMMT received a $2B AstraZeneca convertible-preferred investment and collaboration, adding capital and combo-development access ahead of a Nov 14 PDUFA

Negatives

NTHI’s upcoming FDA meeting and registrational pathway hinge on early-stage data and regulatory feedback, so outcomes are binary and high-risk
Summit’s value near-term is highly PDUFA-dependent; an adverse decision would be a material negative despite the AstraZeneca deal
Iovance’s upgraded guidance depends on continued scaling of manufacturing and treatment-center rollout, leaving execution risk